Who We Are

Who We Are

Oxurion is a biopharmaceutical company developing next generation therapies, designed to improve and better preserve vision in patients with retinal disorders including Geographic Atrophy, the leading cause of vision loss in elderly people worldwide.

Our ambition is to crack the code of GA
While a lot of companies focused their research based on the genetic origins of AMD (e.g. complement pathway), we decided to tackle the disease from a different angle, focusing mainly on the identification of cytoprotective targets through CRISPR-based target discovery platform.

Oxurion is headquartered in Leuven, Belgium, and is listed on Euronext Brussels under the symbol OXUR.

Our Mission

To prevent blindness by pioneering life changing treatments that address unmet medical needs in ophthalmology, with a focus on retinal diseases including Age-related Macular Degeneration (AMD).

Your Vision is
Our Vision

We are united by the shared goal of helping people to see better.

We are collaborative, resilient, and turn challenges into opportunities.

Team

Executive Team

Andy De Deene, MD, MBA

Chief Development Officer

Philippe Barbeaux

Chief Scientific Officer

Board of Directors

Charles Paris de Bollardière

Chairman Of The Board

James Hartmann

Independent Non-Executive Director

Nathalie Laarakker, CPA

Nathalie Laarakker, CPA

Non-Executive, Independent Director

Dr. Anat Loewenstein, MD, MHA

Dr. Anat Loewenstein, MD, MHA

Non-Executive, Independent Director

To inquire regarding partnership opportunities with Oxurion, please contact:

Chief Executive Officer

Pascal Ghoson

Chief Executive Officer and Chief Financial Officer

Prior to being appointed as CEO and CFO of Oxurion, Mr. Ghoson served as CFO of Energisme, an energy intelligence software platform company based in Paris. He was a cofounder of Findrive, which pioneered cars as a service in France. Previously, he was an associate in Mergers & Acquisitions at Rothschild & Co. in Paris; he had previous roles with Goldman Sachs and Lazard in investment banking. He holds a master’s degree in Corporate Finance from the ESSEC Business School in France.

Andy De Deene, MD, MBA

Chief Development Officer

Andy De Deene has extensive experience in drug development, including clinical development, pharmacovigilance and medical affairs. He previously worked as both Manager and Director for the Janssen Research Foundation and XCellentis in Belgium. Andy holds an MD from the University of Ghent, trained as a dermatologist at the University of Cologne, and obtained an executive MBA from Vlerick Management School.

Philippe Barbeaux

Chief Scientific Officer

Mr. Barbeaux brings more than 30 years of experience in the life science industry, including 15 years in ophthalmology with active contribution to the discovery and development of one approved (biologic) and two clinical-stage drug products (small molecule & peptidomimetic). He also has a proven track- record in developing and leading high-performance teams. He previously served as Head of Preclinical and Translational Science at Oxurion before being appointed Chief Scientific Officer. Prior to joining
Oxurion, he was Head of Research and Development at 4C Biotech SA in Seneffe. He did post-doctoral research at the Catholic University of Louvain and was an assistant professor at the Université de Namur. He holds master’s and doctoral degrees in organic chemistry from the Université de Namur.

Charles Paris de Bollardière

(independent non-executive director) – chairman of the Board
Mr. de Bollardière served as Secretary of the Board of Total Énergies, one of the world’s largest energy companies, from 2009 until 2021, capping a 40-year career with the company and its predecessors, including senior level finance roles such as Treasurer. He currently serves on the Governance Committee of the European Issuers Association, is a member of the Legal Committee of ANSA (National Association of Joint Stock Companies) and since 2004, he has been a director of the Caisse Locale du Crédit Agricole Ile de France, Paris-Trocadéro. He holds an engineering degree from l’Ecole Supérieure d’Electricité (CentraleSupélec).

James Hartmann

Independent Non-Executive Director

In 1990, Mr. Hartmann began his career at the U.S. Securities & Exchange Commission (SEC) performing regulatory audits of U.S. investment company complexes.  Mr. Hartmann has also been an in-house Chief Compliance Officer for investment advisers ranging from $1 billion to $500 billion in assets across a wide variety of strategies from venture capital, private credit, and multi-strategy long-short equity and with global offices in major financial centers including New York, London, Tokyo, Singapore and Hong Kong.

In recent years, Mr. Hartmann has been an independent consultant to a variety of investment advisers and broker-dealers regulated primarily by the SEC, FINRA, and the FCA. He has served as an Expert Witness in certain litigated matters and has also served as a Board member for a U.S. mutual fund and a small cap, public healthcare company.  In 2022, the SEC’s Boston Regional office approved Mr.Hartmann to supervise the remediation of an enforcement action against a dual-registrant firm.  Mr. Hartmann has also spoken at conferences to his peers on a wide variety of securities law matters and was an adjunct professor at Fordham University School of Law. He holds a BS degree in Corporate Finance from Indiana University.

Nathalie Laarakker, CPA

Non-Executive, Independent Director
Nathalie Laarakker is an experienced CFO and finance director for multinational companies, with a proven track record of financial and senior level management primarily in the high tech and healthcare industry. She joined Intravace in 2021 from cancer immunotherapies R&D company Gadeta, after having served as their Chief Financial Officer and Managing Director since 2018. She started her professional career at PricewaterhouseCoopers. She qualified as a certified public accountant in 2001, after which she held various senior positions in several companies. Her previous positions included Head of Finance at a US Nasdaq-listed Dutch biotech company Merus. She holds a post doc degree in accountancy from the University of Amsterdam in The Netherlands.

Anat Loewenstein, MD, MHA

Non-Executive, Independent Director
Dr. Loewenstein is a professor and director of the Department of Ophthalmology at the Tel Aviv Medical Center. She is considered one of the top international opinion leaders in the field of vitreoretinal disease and surgery. Dr. Loewenstein has had more than 280 publications in peer-reviewed ophthalmology journals, as well as over 20 book chapters. She has been a principal investigator in multiple multicenter drug and device studies, as well as a variety of investigator driven trials. Her main focus of research interest is early detection of macular degeneration including the development of unique technology, drug toxicity of the retina, drug delivery and penetration into the retina, and the treatment of retinal vascular disease. Dr. Loewenstein has received multiple international recognitions and awards, the most notable being The Macula Society’s Arnall Patz Medal for outstanding contribution in studies of retinal and macular diseases and The Macula Society’s Rosenthal Award.